Journal
HUMAN PATHOLOGY
Volume 45, Issue 6, Pages 1177-1183Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.humpath.2014.01.014
Keywords
CRABP-II; Pancreatic duct adenocarcinoma; Pancreatic intraepithelial neoplasm; Retinoic acid; Cytology; Immunohistochemistry; Pathology
Categories
Funding
- Department of Pathology, University Hospital Case Medical Center
- School of Medicine at Western Reserve University
Ask authors/readers for more resources
CRABP-II, a retinoic acid binding protein, shuffles retinoic acid from cytoplasm into nucleus and forms a complex with nuclear retinoic acid receptor to facilitate transcriptional activities of retinoic acid. In this study, we studied the expression patterns of CRABP-II in pancreatic ductal adenocarcinoma (PDAC) compared with those in normal pancreas, chronic pancreatitis, and precancerous lesions. We showed no detectable expressions of CRABP-II in normal pancreatic parenchyma, normal ductal epithelium, and chronic pancreatitis. In contrast, the expression of CRABP-II was readily detected in all PDACs including metastatic PDACs. CRABP-II staining was also observed and progressively increased from pancreatic intraepithelial neoplasia 1 to 3. In addition, when fine needle aspiration specimens were evaluated from patients with PDAC, CRABP-II was positive in 55.6% cases if cytology diagnosis was atypia, and in 87.5% cases, if malignancy. Our study suggests that CRABP-II is highly and specifically expressed in PDAC and is more commonly expressed in high-grade precursor cancerous lesions than in low-grade lesions. Therefore, overexpression of CRABP-LE is a late event of pancreatic carcinogenesis, and it could be used as a diagnostic marker to distinguish PDAC from other benign pancreatic conditions in both resection and cytology specimens. (C) 2014 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available